Gestanon

Quick links to important sections

Gestanon

Method of action: Progestogen

Treatment option: Miscarriage

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Gestanon

Property Description
Active ingredient Allylestrenol (C21H32O)
Form Oral tablet
Pharmacological Class Progestin / Synthetic Steroid
Common Use Hormonal support / Luteal phase support
Origin Synthetic, 19-nortestosterone derivative

What Type of Medicine is Gestanon?

Gestanon is a prescription medication whose active ingredient is Allylestrenol, a compound classified under the pharmacological class of progestins and a synthetic steroid. It belongs to the broader category of hormone therapy, designed to supplement or mimic the effects of the naturally occurring hormone progesterone in the body. Allylestrenol is chemically defined as a 19-nortestosterone derivative, which confirms its synthetic origin as a specialized, lab-created compound designed for systemic use. This progestin is recognized for its stability and effectiveness following oral administration.


Composition, Form, and Chemical Origin

The medication is supplied as an oral formulation in the form of a tablet, making the route of administration oral. Allylestrenol is the singular active ingredient within the formulation, making Gestanon a single-entity product used exclusively for providing pure progestational effects. Its synthetic composition and stability in the tablet form ensure that a precise, measured dose is delivered, distinguishing it from certain formulations of natural progesterone. Its designation as an orally active progestogen is a key feature that simplifies the administration regimen for patients.


What is the General Purpose of Allylestrenol?

The general purpose of Allylestrenol is to provide targeted progestational support by acting as a strong progesterone receptor agonist. This essential physiological action ensures the drug mimics the biological effects of natural progesterone, primarily helping to maintain and stabilize the lining of the uterus (endometrium). Allylestrenol's fundamental role is centered on providing necessary luteal phase support for adult women of childbearing age and pregnant women who require hormonal stabilization, such as in managing conditions related to progesterone insufficiency. The medicine is clinically recognized for its ability to maintain the hormonal environment crucial for reproductive health.

Regulatory References

  1. Allylestrenol (MeSH Record)

What side effects are possible with Gestanon?

Possible Side Effects and Safety Information

Allylestrenol (Gestanon) is a progestin whose safety profile is officially documented by government regulatory agencies (such as those providing the SmPC/prescribing information) and is classified into categories based on frequency and body systems. The profile primarily distinguishes between common, expected effects and rare, serious safety constraints.


Adverse Reaction Classification

Regulatory documents classify side effects into frequency bands, with the most frequently documented adverse reactions typically being categorized as Common. These include effects such as nausea, vomiting, headache, and dizziness, alongside breast tenderness and sometimes fluid retention.

Adverse effects are also formally grouped by the body system affected (System-Organ Class), with frequently cited systems being Gastrointestinal Disorders, Nervous System Disorders, and Reproductive System Disorders.


Serious Adverse Reactions and Safety Restrictions

Official labeling documents significant safety constraints and potential serious adverse reactions. The medicine is formally contraindicated (should not be used) in patients with severe, active Hepatic Disease (liver dysfunction) or a history of Thromboembolic Disorders (blood clot formation), as well as in cases of Hormone-Dependent Carcinoma and Undiagnosed Vaginal Bleeding.

Regulatory summaries note caution for use in special populations, particularly a documented restriction that Allylestrenol is not recommended during Lactation. Furthermore, caution is advised for patients with pre-existing conditions like Asthma or Renal/Kidney Disease due to the potential for fluid retention.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information for Allylestrenol (Gestanon) describes the acute toxicity profile of the medication following an overdosage. The available prescribing information indicates that overexposure resulting from the ingestion of several tablets is generally considered to be of low acute toxicity. Consequently, formal documentation states that such an event is typically not associated with a cause for great concern. This assessment reflects that no specific severe or life-threatening clinical manifestations are formally documented as expected outcomes of acute overdosage in the official regulatory text.


Required Emergency Actions

The mandated action following any suspected overdosage of Gestanon is to consult your doctor or a qualified healthcare professional. This instruction serves as the official help-seeking trigger required by regulatory authorities for formal assessment and guidance. Since the drug is documented to have low acute toxicity, the official label does not mandate immediate emergency services but rather medical consultation.


Management and Treatment

Management of Allylestrenol overdosage is limited to symptomatic and supportive treatment. This approach focuses on maintaining the patient's physiological stability and managing any clinical changes that may occur. The official regulatory documents confirm that no specific antidote is known for Allylestrenol. There are no population-specific considerations regarding increased overdose severity in special groups formally documented in the official prescribing information.

Therapeutic Uses of Gestanon

Gestanon (allylestrenol) is a progestogen applied in addressing conditions where supportive hormonal therapy is needed for gestation. It supports physiological stability during pregnancy. Allylestrenol is commonly used to help with symptomatic relief and is applied in addressing conditions within several therapeutic domains: managing Threatened Miscarriage, addressing the chronic risk of Habitual (Recurrent) Abortion, and providing support for conditions like Threatened Premature Labor and luteal phase defect.

The medication is applicable in contexts marked by increased discomfort related to acute risks, such as unexpected vaginal bleeding or lower abdominal pain. It helps address symptoms related to uterine instability and heightened physiological activity, which may interfere with daily comfort. The support is intended to assist the patient during difficult episodes by easing distress and assisting with maintaining functional stability.


Quick Fact: Relief for Uterine Instability Gestanon is commonly used to help manage symptoms related to uterine irritability and recurrent pregnancy loss, applied in clinical settings where short-term symptomatic assistance is needed to assist with managing associated symptom patterns.

Eligibility and Restrictions for Use

Gestanon (progesterone) is authorized for use in women as part of an Assisted Reproductive Technology (ART) treatment program, typically up to 10 weeks of pregnancy, for corpus luteal function supplementation.

Populations for whom use is contraindicated

Use is strictly contraindicated for individuals with several clinical conditions, as documented in official regulatory labeling for progesterone products. These conditions include:

  • Hypersensitivity: Known allergy or previous reaction to progesterone or any ingredient of the product.
  • Malignancy: Known or suspected malignancy of the breast or genital organs.
  • Thromboembolism: Active arterial or venous thromboembolism, or a history of these events.
  • Liver Disease: Severe hepatic impairment or active liver disease.
  • Other Conditions: Undiagnosed abnormal genital bleeding or a known missed abortion.

Eligibility-related restrictions

Official labeling states the drug is not intended for pediatric use or for women 65 years of age and older. Caution is advised and use is not recommended with other vaginal products, as this may alter the drug's absorption. Women with a history of depression require close observation, and the medicine should be discontinued if symptoms worsen.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Allylestrenol (Gestanon) is subject to documented interaction patterns that primarily involve changes in drug exposure or modifications of co-administered medications, as detailed in regulatory prescribing information.

Pharmacokinetic and Metabolic Interactions

Co-administration with medicines that are known hepatic enzyme inducers can significantly affect Allylestrenol plasma concentrations. This category includes certain antiepileptics, such as phenytoin and carbamazepine, and anti-tuberculosis agents like rifampicin.

  • Official Outcome: The resulting increased metabolism of Allylestrenol leads to reduced plasma levels, which can decrease its overall therapeutic effectiveness. The herbal product St. John's Wort (Hypericum perforatum), a recognized enzyme inducer, is also associated with a decrease in Allylestrenol plasma concentrations.

Pharmacodynamic Interactions

Documented interactions highlight potential additive or modifying effects on other drug classes:

  • Oral Anticoagulants: Concurrent use with agents such as warfarin may alter the anticoagulant effect, requiring regulatory acknowledgement of this potential change.
  • Antidiabetic Medications: Progestogens like Allylestrenol may impact glucose tolerance, necessitating consideration of potential alterations in the required dosage of insulin or other antidiabetic medications.

Administration Constraints

No formal timing or separation requirements for the administration of Allylestrenol relative to other products are explicitly documented in major regulatory labeling. Furthermore, no specific drug-drug combinations are formally classified as contraindicated based purely on interaction risk alone.

Mechanism of Action

How Gestanon Works

Gestanon is the brand name for allylestrenol, a synthetic progestogen. Its action is strictly defined by its role as an agonist at the progesterone receptor (PR), mimicking the activity of the endogenous hormone progesterone.


Progesterone Receptor Agonism

Allylestrenol engages in receptor-mediated signaling by binding to the progesterone receptor. This interaction promotes the nuclear translocation of the receptor complex, which then modulates the transcription of specific target genes within the cell nucleus. This pathway activity facilitates the cellular and morphological transition of the endometrium from a proliferative to a secretory phenotype.


Myometrial and Trophoblastic Modulation

The compound influences downstream molecular steps, resulting in localized physiological consequences within the uterus. PR agonism promotes specific alterations in ion flux and regulatory protein expression in uterine smooth muscle (myometrium). This effect manifests as reduced contractility of the myometrial tissue. Furthermore, allylestrenol influences signaling patterns within trophoblast cells, modifying local cellular processes.

Dosage and Administration Information

Gestanon (allylestrenol) is an oral medication administered strictly as a 5 mg tablet. The overall use protocol is defined by specific schedules based on the clinical context. The medicine is not recommended for administration to children and adolescents younger than 16 years old.

The drug is utilized in varying dosage ranges. For maintenance and preventative protocols, such as habitual miscarriage, administration typically ranges from 5 mg to 10 mg once daily. Conversely, for situations requiring acute support, such as threatened miscarriage or Intra Uterine Growth Retardation (IUGR), the regimen involves a higher dose, typically 15 mg total per day, divided into three separate administrations. For specific high-support contexts like threatened premature labor, dosages can escalate up to 40 mg daily, determined individually.

Duration patterns are strictly delineated. Acute support is generally limited to a short-term course of 5 to 7 days, or until stabilization occurs. Maintenance use for habitual miscarriage requires continued administration for at least one month beyond the critical period of pregnancy. A required procedural step for most regimens is the gradual reduction or tapering of the dose after symptoms disappear or stabilize. If a dose is missed, the regular schedule is continued and a double dose is not taken to compensate.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Gestanon

The clinical evaluation of the active ingredient, allylestrenol, has explored its use for two main indications: threatened miscarriage and recurrent (habitual) abortion. The evidence includes randomized controlled trials (RCTs) and various comparative studies focused on adult women during the first and second trimesters. Researchers primarily examined obstetric outcomes, including live birth rates, rates of ongoing pregnancy, and the frequency of pregnancy loss. Findings describe patterns observed in the populations studied. Much of the data is derived from trials that compared allylestrenol against other progestin medications, rather than against a non-treatment group.


Research in the Context of Luteal Phase Support (LPS)

The evaluation of allylestrenol for luteal phase support (LPS) following assisted reproductive techniques (ART) relies mainly on retrospective observational studies. These studies monitored clinical endpoints such as the clinical pregnancy rate and live birth rate. Scientific reviews suggest that the evidence level for this specific indication is generally considered lower due to the reliance on observational data. Furthermore, comparative evidence is lacking regarding a direct assessment against an inert control.


Research Gaps and Limitations

The research primarily addresses short-term outcomes until delivery. Long-term effects are not fully established regarding the sustained health or neurodevelopment of children who were exposed to the medication. Evidence quality varies across studies, and some studies have modest sample sizes. The results apply only to the populations studied, meaning certainty remains low in areas where data for certain groups are insufficient.

Frequently Asked Questions (FAQ)

Common questions about Gestanon (FAQ)


Q: Are weight changes a possible side effect of Gestanon?

A: Official product information, which details the safety profile of the medicine, sometimes includes a 'change in weight' or 'slight weight gain' among the reported side effects. This potential effect may be associated with fluid retention, which is also commonly documented in regulatory summaries.


Q: Is there a link between Gestanon and mood changes?

A: Regulatory documents classify some potential side effects under Nervous System Disorders. Some official sources explicitly note that mood changes, such as irritation, depression, or anxiety, may potentially be experienced by some patients.


Q: Do I need a prescription from a doctor to get Gestanon?

A: Gestanon (allylestrenol) is generally classified with a legal status that requires a medical prescription for it to be dispensed.


Q: Is Gestanon a type of steroid medication?

A: Gestanon is described chemically by authorities as a synthetic steroid with progestational activity. Specifically, it is a synthetic progestogen, meaning it mimics the activity of the natural hormone progesterone.


Q: Is Gestanon used for any other purpose besides its main approved uses?

A: While the main global indications are related to pregnancy support, official drug documents in some specific regions, such as Japan, describe its use for benign prostatic hyperplasia (BPH) in men. The medication has also been studied for certain gynecological disorders like irregular menstruation, according to regulatory reviews of clinical data.


Q: Is it normal to feel a change in appetite when using Gestanon?

A: A change in appetite is not typically listed as a primary, common adverse reaction in most regulatory summaries. However, some official documentation associates reported weight changes with a possible increase in appetite.


Q: Is hair loss mentioned in the official side effects documents for Gestanon?

A: Official side effect profiles frequently list 'unwanted hair growth' (hirsutism) as a potential effect. Hair loss (alopecia) is not generally listed among the commonly reported side effects in official regulatory summaries.


Q: Can Gestanon be taken with vitamins or dietary supplements?

A: Regulatory documents explicitly mention that co-administration with the herbal product St. John's Wort can lead to reduced plasma concentrations of Gestanon. Specific interactions with other common vitamins or general dietary supplements are not broadly detailed in these official summaries.


Q: What should I look out for that might signal a serious side effect from Gestanon?

A: Official warnings advise patients to seek medical help immediately if they experience signs of a serious problem. These include sudden chest pain, shortness of breath, severe abdominal pain, swelling or pain in the legs (potential signs of blood clot formation), or yellowing of the skin or eyes (potential sign of liver dysfunction).


Q: Can men use Gestanon for any condition?

A: Official information indicates that the compound has been studied and is used in certain regions, such as Japan, for the treatment of Benign Prostatic Hyperplasia (BPH) in men.


Q: Are there special considerations for taking Gestanon if I have kidney issues?

A: Regulatory documents advise that caution should be exercised for patients with pre-existing kidney disease or renal dysfunction, often due to the potential for fluid retention. This is a common precaution noted for progestogen medications.


Q: Does Gestanon impact fertility or reproductive health?

A: The medication is clinically used to support pregnancy. However, regulatory hazard information for the active substance classifies it as 'Suspected of damaging fertility or the unborn child' outside of its specific clinical application, reflecting general pharmacological properties. Information regarding its general impact on fertility outside of its indicated use is detailed in official sources.


Q: Are there different forms (tablet, liquid, injection) of Gestanon available?

A: Gestanon is primarily available as an oral tablet. Official documentation detailing dosage forms typically confirms the oral tablet form and does not broadly list injectable or extended-release liquid formulations.


Q: Are there any known drug interactions with common anti-depressants and Gestanon?

A: Regulatory interaction summaries do not typically mention specific antidepressant drugs by name. However, official documents caution against concurrent use with medications that are known to be 'hepatic enzyme inducers' (medications that speed up liver metabolism), as this can lead to reduced Gestanon effectiveness in the body.


Q: Why is the mechanism of action for Gestanon described as 'selective'?

A: Allylestrenol is sometimes described in pharmacology literature as a 'pure progestogen.' This term is used because it is reported to be devoid of significant androgenic, estrogenic, or glucocorticoid activity, meaning its effects are limited primarily to the progesterone receptor.


Q: Do studies suggest Gestanon is more effective for some patient groups than others?

A: The official research evidence notes that the results and certainty of effect from clinical trials apply specifically to the populations that were studied. This means data may be less sufficient or unavailable for other patient groups, resulting in lower certainty regarding its effects in those populations.


Q: Is fatigue or tiredness a common experience when starting Gestanon?

A: Official side effect profiles list fatigue or tiredness as a possible adverse reaction. This is one of the generally reported effects noted in the regulatory safety documentation.


Q: Does Gestanon require any special monitoring while I am taking it?

A: For its use in pregnancy support, regulatory documents often advise that routine check-ups are necessary. These may include blood hormone monitoring and ultrasound examinations, according to official prescribing information.


Q: What is the difference between Gestanon and its generic version?

A: Gestanon is the brand name chosen by the manufacturer. The generic name for the active medicine contained in the tablet is allylestrenol. The generic version is chemically identical to the active ingredient in the brand-name product.


Q: Why do some people experience initial side effects that fade away?

A: Some official descriptions of common side effects, such as nausea and vomiting, note that they are often experienced in the initial stages of treatment. This is generally understood to be related to the body adjusting to the introduction of the medication.


Q: How does Gestanon affect the body's natural hormone levels?

A: As a progestogen, it acts as an agonist at the progesterone receptor, mimicking the effects of natural progesterone. Clinical data indicates that it can stimulate the body's placental progesterone production. In men, high doses have been found to considerably decrease circulating testosterone levels.


Q: Are there any reports of Gestanon causing allergic reactions?

A: Official documentation notes that a hypersensitivity or allergy to allylestrenol or its components is a contraindication (a reason the drug should not be used). Allergic reactions, including rash or swelling, are listed as serious adverse reactions that would require discontinuation of the medication.


Q: Can Gestanon be crushed or split if it is a tablet form?

A: Regulatory guidance on administration for the tablet form typically advises swallowing the tablet whole. Official instructions generally state that the tablet form is intended to be swallowed whole and is not meant to be crushed, broken, or chewed.


Q: Is there any research evidence on Gestanon's use in combination with other treatments?

A: Clinical study summaries show that administration has been reviewed in combination with non-drug treatments like bed rest for threatened abortion. Studies have also compared its efficacy against other progestins, like dydrogesterone.


Q: Does Gestanon interact with common over-the-counter pain relievers?

A: Regulatory guidance on administration does not generally document formal timing or separation requirements for Gestanon relative to other products. The official summaries primarily detail interactions with prescription drug classes like anti-epileptics or anti-diabetic medications, rather than specifying common over-the-counter pain relievers.


Q: Does Gestanon have any restrictions for use in teenagers?

A: The official prescribing information states that Gestanon is not recommended for administration to children and adolescents younger than 16 years old. Information specific to the age group between 16 and 18 years old is generally determined based on the clinical indication, as the restriction applies to those younger than 16.


Q: Is Gestanon safe to use during pregnancy?

A: Gestanon is officially approved and indicated for use in the first and second trimesters of pregnancy for specific conditions, such as threatened miscarriage and recurrent abortion. Its use in this context is based on clinical trials and established regulatory approvals for these indications.


Q: What does the official drug label say about Gestanon and driving a car?

A: Official safety documents list dizziness as a common side effect, which affects the nervous system. The specific advisory statement regarding operating vehicles is detailed in the full official drug label.

How should Gestanon be stored and disposed of?

Storage and Handling Requirements

Gestanon (allylestrenol) tablets must be stored according to official regulatory specifications to maintain product integrity. The medication should be kept at room temperature and generally stored below 30 C as documented in product labeling. It is mandatory to keep the tablets in the original container or blister packaging to protect the active ingredient from light and moisture.

Child Safety

All regulatory documents strictly mandate that Gestanon must be kept out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

Unused or expired Gestanon must be disposed of safely and responsibly. Regulatory guidance instructs users to not dispose of the medicine via household trash or wastewater. The proper procedure involves returning the product to a pharmacist or designated collection site for disposal in accordance with local and national pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Gestanon found in:

A-Z Index: